A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer
A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer
This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer. The study will compare the effectiveness of each regimen in shrinking tumors and extending the lives of women with erbB-2 (HER2) positive breast cancer. The study will also compare the safety of the two regimens and as well as the quality of life of subjects receiving either regimen.
Inclusion Criteria:
Exclusion Criteria:
St Louis, Missouri 63110, United States
Paramus, New Jersey 07652, United States
Charleston, South Carolina 29425, United States
Charleston, West Virginia 25304, United States
Greenfield Park, Quebec J4V 2H1, Canada
Beijing, 100071, China
Strasbourg, 67000, France
Nashilk, Maharashtra 422005, India
Tokyo, Bunkyo-ku 113-8677, Japan
Ehime, Matsuyama-city 791-0280, Japan
Hokkaido, Sapporo-shi 003-0804, Japan
Hiroshima, 737-0023, Japan
Vilnius, LT-08660, Lithuania
Jelenia Góra, Lower Silesian Voivodeship 58-506, Poland
Olsztyn, Warmian-Masurian Voivodeship 10228, Poland
Johannesburg, Gauteng 2197, South Africa
Santiago de Compostela, Galicia 15706, Spain
PAU de Sanchinarro, Madrid 28050, Spain
Chernivtsi, 58013, Ukraine
Donetsk, 83092, Ukraine
Mariupil, 87500, Ukraine
London, SE1 9RT, United Kingdom